Cellular Crosstalk of Dendritic Cells and Identification of 2 Novel Biomarkers for Psoriasis

A recent study, published in Frontiers in Immunology, examined the impact of dendritic cells (DCs) on T cell crosstalk in psoriasis, elucidated the characterization of fatty acid binding protein 5 (FABP5) and killer cell lectin-like receptor B1 (KLRB1) as biomarkers in psoriasis, and highlighted the promise and value of tofacitinib in psoriasis therapy targeting DCs.

Researchers employed bioinformatics, machine learning, and statistical methods to dissect psoriasis pathogenesis and identify potential biomarkers for diagnosis and treatment.

Analyzing single-cell sequencing data, the study revealed the regulatory role of DCs in activating T cells through the CD70/CD27 signaling pathway, shedding light on the inflammatory response mechanism in psoriasis. FABP5 and the KLRB1 emerged as upregulated biomarkers, showing colocalization in psoriatic skin tissues and M5-induced HaCaT cells, implicating their involvement in psoriasis development.

Furthermore, the study evaluated the efficacy of 6 commonly prescribed drugs for psoriasis treatment, focusing on their modulation of the DC-associated pathway. Notably, tofacitinib showed promise in targeting DCs for psoriasis therapy.

Validation through reverse transcription-quantitative polymerase chain reaction, immunohistochemistry, and immunofluorescence assays supported the findings, consolidating the regulatory role of DC-T cell crosstalk and the potential of FABP5 and KLRB1 as biomarkers for psoriasis diagnosis and treatment.

In conclusion, this comprehensive analysis advances our understanding of psoriasis pathogenesis, identifies potential biomarkers, and underscores the therapeutic potential of targeting dendritic cells, offering insights for future research and clinical interventions in psoriasis management.

Reference
Ma Z, An P, Hao S, et al. Single-cell sequencing analysis and multiple machine-learning models revealed the cellular crosstalk of dendritic cells and identified FABP5 and KLRB1 as novel biomarkers for psoriasis. Front Immunol. Published online March 26, 2024. doi:10.3389/fimmu.2024.1374763